EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Multicenter randomized effectiveness/implementation trial of a digital self-management support tool to improve the quality of life during adjuvant hormonal therapy for patients with early breast cancer: The HOPE trial

Maria Alice Franzoi, Stefan Michels, Sarah Ball, Aude Barbier, Chloe Serhal, Alicia Bernatowiez, Arlindo Ferreira, Juliete Fanton D'Andon, Francois Gernier, Adeline Morel, Julie Demetz, Fanny Le Du und 2 weitere

Contemporary Clinical Trials · 2026

DOI: 10.1016/j.cct.2026.108407 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Contemporary Clinical Trials, 2026. Verfasst von Maria Alice Franzoi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Survivorship | U1018-CESP Gustave Roussy, INSERM, Université Paris Saclay, France. Electronic address: mariaalice.borinelli-franzoi@gustaverou…. Hauptthemen laut MEDLINE: Breast Neoplasms, Quality of Life, Self-Management, Antineoplastic Agents, Hormonal. Die Arbeit nennt 54 Literaturangaben. Gefördert von: Institut National Du Cancer, Fondation Gustave Roussy.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: For patients with hormone receptor (HR) positive early breast cancer (BC), adjuvant endocrine therapy (ET) represents the cornerstone of treatment. However, 75% of patients experience ET-related symptoms that negatively affect their quality of life (QOL). Despite their high prevalence, these symptoms are often underestimated and under-addressed during consultations. As a result, non-adherence to ET is common and remains a major barrier for optimal disease and survival outcomes. METHODS: National, prospective, randomized, open-label hybrid type 1 effectiveness/implementation trial conducted in France comparing a personalized digital health pathway plus standard of care (SoC) vs. SoC alone in patients with HR+ early BC reporting ET-related symptoms. 180 patients will be randomized 1:1 to receive either 12 weeks of the digital health pathway or 12 weeks of SoC. The intervention is anchored by the Resilience© digital companion including remote symptom and needs assessment, an introductory nurse-navigator phone call, and access to personalized, symptom-specific online educational and self-management programs (physical activity, yoga, meditation or cognitive behavioral therapy). In both arms, patients will be invited to wear a wearable device to objectively monitor behavioral parameters. The primary endpoint is the ET symptoms scale of the European Organization for Research and Treatment of Cancer (EORTC) QLQ-BR45 over 12-weeks. Secondary endpoints include other QOL domains, self-reported ET adherence, eHealth literacy, self-efficacy, and evaluation of the implementation process. DISCUSSION: This study should provide evidence on the effectiveness and real-world implementation of a personalized digital health pathway to improve QOL in patients experiencing ET-related symptoms. TRIAL REGISTRATION: ClinicalTrials.gov NCT06781996; Protocol version 3.0.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsQuality of LifeSelf-ManagementAntineoplastic Agents, HormonalHumansFemaleDigital HealthProspective StudiesFranceChemotherapy, AdjuvantAdultMiddle Aged

Stichwörter der Autor:innen

Adjuvant endocrine therapyDigital healthEarly breast cancerNurse navigationQuality of lifeSelfmanagement support

Substanzen

Antineoplastic Agents, Hormonal

Autor:innen und Institutionen

  • Cancer Survivorship | U1018-CESP Gustave Roussy, INSERM, Université Paris Saclay, France. Electronic address: mariaalice.borinelli-franzoi@gustaveroussy.fr.
  • Biostatistics and Epidemiology Department, Gustave Roussy, Villejuif, France.
  • Cancer Survivorship | U1018-CESP Gustave Roussy, INSERM, Université Paris Saclay, France.
  • Clinical Research Department, Gustave Roussy, Villejuif, France.
  • Resilience, Paris, France.
  • Centre François Baclesse, Caen, France; INSERM, U1086, Caen, France.

Förderung

  • Institut National Du Cancer
  • Fondation Gustave Roussy

Zitieren

APA

Franzoi, M. A., Michels, S., Ball, S., Barbier, A., Serhal, C., Bernatowiez, A., Ferreira, A., D'Andon, J. F., Gernier, F., Morel, A., Demetz, J., Le Du, F., Lapidari, P., & Vaz-Luis, I. (2026). Multicenter randomized effectiveness/implementation trial of a digital self-management support tool to improve the quality of life during adjuvant hormonal therapy for patients with early breast cancer: The HOPE trial. Contemporary Clinical Trials. https://doi.org/10.1016/j.cct.2026.108407

Vancouver

Franzoi MA, Michels S, Ball S, Barbier A, Serhal C, Bernatowiez A, et al. Multicenter randomized effectiveness/implementation trial of a digital self-management support tool to improve the quality of life during adjuvant hormonal therapy for patients with early breast cancer: The HOPE trial. Contemporary Clinical Trials. 2026. doi:10.1016/j.cct.2026.108407

BibTeX
@article{Franzoi2026,
  author = {Franzoi, Maria Alice and Michels, Stefan and Ball, Sarah and Barbier, Aude and Serhal, Chloe and Bernatowiez, Alicia and Ferreira, Arlindo and D'Andon, Juliete Fanton and Gernier, Francois and Morel, Adeline and Demetz, Julie and Le Du, Fanny and Lapidari, Pietro and Vaz-Luis, Ines},
  title = {Multicenter randomized effectiveness/implementation trial of a digital self-management support tool to improve the quality of life during adjuvant hormonal therapy for patients with early breast cancer: The HOPE trial},
  journal = {Contemporary Clinical Trials},
  year = {2026},
  doi = {10.1016/j.cct.2026.108407}
}
Kostenlos starten →